Skip to main content
Top
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Lung Cancer | Research article

Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees

Authors: Huan Lin, Gong Zhang, Xu-chao Zhang, Xin-lei Lian, Wen-zhao Zhong, Jian Su, Shi-liang Chen, Yi-long Wu

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

There were scarcely germline variants of familial lung cancer (LC) identified. We conducted an study with whole-exome sequencing of pedigrees with familial lung cancer to analyze the potential genetic susceptibility.

Methods

Probands with the highest hereditary background were identified by our large-scale epidemiological study and five ones were enrolled as a learning set. The germline SNPs (single-nucleotide polymorphisms) of other five similar probands, four healthy individuals in the formerly pedigrees and three patients with sporadic LC were used as a validation set, controlled by three healthy individuals without family history of any cancer. The network of mutated genes was generated using STRING-DB and visualized using Cytoscape.

Results

Specific and shared somatic mutations and germline SNPs were not the shared cause of familial lung cancer. However, individual germline SNPs showed distinct protein-protein interaction network patterns in probands versus healthy individuals and patients with sporadic lung cancer. SNP-containing genes were enriched in the PI3K/AKT pathway. These results were validated in the validation set. Furthermore, patients with familial lung cancer were distinguished by many germline variations in the PI3K/AKT pathway by a simple SVM classification method. It is worth emphasizing that one person with many germline variations in the PI3K/AKT pathway developed lung cancer during follow-up.

Conclusions

The phenomenon that the enrichments of germline SNPs in the PI3K/AKT pathway might be a major predictor of familial susceptibility to lung cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. J Natl Cancer Inst. 1963;30(2):289–312.PubMed Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. J Natl Cancer Inst. 1963;30(2):289–312.PubMed
2.
go back to reference An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One. 2012;7(6):e40109.CrossRef An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One. 2012;7(6):e40109.CrossRef
3.
go back to reference Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–58.CrossRef Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–58.CrossRef
4.
go back to reference Leiserson MDM, Vandin F, Wu HT, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet. 2015;47(2):106.CrossRef Leiserson MDM, Vandin F, Wu HT, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet. 2015;47(2):106.CrossRef
5.
go back to reference Xu H, Spitz MR, Amos CI, et al. Complex segregation analysis reveals a multigene model for lung cancer. Hum Genet. 2005;116(1–2):121–7.CrossRef Xu H, Spitz MR, Amos CI, et al. Complex segregation analysis reveals a multigene model for lung cancer. Hum Genet. 2005;116(1–2):121–7.CrossRef
6.
go back to reference Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633.CrossRef Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633.CrossRef
7.
go back to reference Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25. 1. Nature genetics. 2008;40(5):616.CrossRef Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25. 1. Nature genetics. 2008;40(5):616.CrossRef
8.
go back to reference Jin G, Ma H, Wu C, et al. Genetic variants at 6p21. 1 and 7p15. 3 are associated with risk of multiple cancers in Han Chinese. Am J Hum Genet. 2012;91(5):928–34.CrossRef Jin G, Ma H, Wu C, et al. Genetic variants at 6p21. 1 and 7p15. 3 are associated with risk of multiple cancers in Han Chinese. Am J Hum Genet. 2012;91(5):928–34.CrossRef
9.
go back to reference Lan Q, Hsiung CA, Matsuo K, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet. 2012;44(12):1330.CrossRef Lan Q, Hsiung CA, Matsuo K, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet. 2012;44(12):1330.CrossRef
10.
go back to reference Shiraishi K, Kunitoh H, Daigo Y, et al. A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population. Nat Genet. 2012;44(8):900.CrossRef Shiraishi K, Kunitoh H, Daigo Y, et al. A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population. Nat Genet. 2012;44(8):900.CrossRef
11.
go back to reference Wang Y, Broderick P, Webb E, et al. Common 5p15. 33 and 6p21. 33 variants influence lung cancer risk. Nature genetics. 2008;40(12):1407.CrossRef Wang Y, Broderick P, Webb E, et al. Common 5p15. 33 and 6p21. 33 variants influence lung cancer risk. Nature genetics. 2008;40(12):1407.CrossRef
12.
go back to reference Liu Y, Kheradmand F, Davis CF, et al. Focused analysis of exome sequencing data for rare germline mutations in familial and sporadic lung cancer. J Thorac Oncol. 2016;11(1):52–61.CrossRef Liu Y, Kheradmand F, Davis CF, et al. Focused analysis of exome sequencing data for rare germline mutations in familial and sporadic lung cancer. J Thorac Oncol. 2016;11(1):52–61.CrossRef
13.
go back to reference Ganna A, Verweij KJH, Nivard MG, et al. Large-scale GWAS reveals insights into the genetic architecture of same-sex sexual behavior. Science. 2019;365(6456):eaat7693.CrossRef Ganna A, Verweij KJH, Nivard MG, et al. Large-scale GWAS reveals insights into the genetic architecture of same-sex sexual behavior. Science. 2019;365(6456):eaat7693.CrossRef
14.
go back to reference Davies G, Marioni RE, Liewald DC, et al. Genome-wide association study of cognitive functions and educational attainment in UK biobank (N= 112 151). Mol Psychiatry. 2016;21(6):758.CrossRef Davies G, Marioni RE, Liewald DC, et al. Genome-wide association study of cognitive functions and educational attainment in UK biobank (N= 112 151). Mol Psychiatry. 2016;21(6):758.CrossRef
15.
go back to reference Okbay A, Beauchamp JP, Fontana MA, et al. Genome-wide association study identifies 74 loci associated with educational attainment. Nature. 2016;533(7604):539.CrossRef Okbay A, Beauchamp JP, Fontana MA, et al. Genome-wide association study identifies 74 loci associated with educational attainment. Nature. 2016;533(7604):539.CrossRef
16.
go back to reference Lin H, Huang YS, Yan H, et al. A family history of cancer and lung cancer risk in never-smokers: a clinic-based case–control study. Lung Cancer. 2015;89(2):94–8.CrossRef Lin H, Huang YS, Yan H, et al. A family history of cancer and lung cancer risk in never-smokers: a clinic-based case–control study. Lung Cancer. 2015;89(2):94–8.CrossRef
17.
go back to reference Xiao CL, Mai ZB, Lian XL, et al. FANSe2: a robust and cost-efficient alignment tool for quantitative next-generation sequencing applications. PLoS One. 2014;9(4):e94250.CrossRef Xiao CL, Mai ZB, Lian XL, et al. FANSe2: a robust and cost-efficient alignment tool for quantitative next-generation sequencing applications. PLoS One. 2014;9(4):e94250.CrossRef
18.
go back to reference Wu X, Xu L, Gu W, et al. Iterative genome correction largely improves proteomic analysis of nonmodel organisms. J Proteome Res. 2014;13(6):2724–34.CrossRef Wu X, Xu L, Gu W, et al. Iterative genome correction largely improves proteomic analysis of nonmodel organisms. J Proteome Res. 2014;13(6):2724–34.CrossRef
19.
go back to reference Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2012;41(D1):D808–15.CrossRef Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2012;41(D1):D808–15.CrossRef
20.
go back to reference Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.CrossRef Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.CrossRef
21.
go back to reference Lin H, Zhong WZ, Yang XN, et al. A clinical model to estimate the pretest probability of lung cancer, based on 1198 pedigrees in China. J Thorac Oncol. 2012;7(10):1534–40.CrossRef Lin H, Zhong WZ, Yang XN, et al. A clinical model to estimate the pretest probability of lung cancer, based on 1198 pedigrees in China. J Thorac Oncol. 2012;7(10):1534–40.CrossRef
22.
go back to reference Carnero A, Paramio JM. The PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol. 2014;4:252.CrossRef Carnero A, Paramio JM. The PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol. 2014;4:252.CrossRef
23.
go back to reference Dienstmann R, Rodon J, Serra V, et al. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021–31.CrossRef Dienstmann R, Rodon J, Serra V, et al. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021–31.CrossRef
24.
go back to reference Martini M, De Santis MC, Braccini L, et al. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372–83.CrossRef Martini M, De Santis MC, Braccini L, et al. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372–83.CrossRef
25.
go back to reference Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, et al. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics. 2015;16(16):1843–62.CrossRef Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, et al. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics. 2015;16(16):1843–62.CrossRef
26.
go back to reference Cardona AF, Zatarain-Barrón ZL, Rubio C, et al. Probable hereditary familial overlap syndrome with multiple synchronous lung tumors. Lung Cancer. 2018;124:279–82.CrossRef Cardona AF, Zatarain-Barrón ZL, Rubio C, et al. Probable hereditary familial overlap syndrome with multiple synchronous lung tumors. Lung Cancer. 2018;124:279–82.CrossRef
27.
go back to reference Kanwal M, Ding XJ, Ma ZH, et al. Characterization of germline mutations in familial lung cancer from the Chinese population. Gene. 2018;641:94–104.CrossRef Kanwal M, Ding XJ, Ma ZH, et al. Characterization of germline mutations in familial lung cancer from the Chinese population. Gene. 2018;641:94–104.CrossRef
28.
go back to reference Musolf AM, Simpson CL, De Andrade M, et al. Familial lung cancer: a brief history from the earliest work to the most recent studies. Genes. 2017;8(1):36.CrossRef Musolf AM, Simpson CL, De Andrade M, et al. Familial lung cancer: a brief history from the earliest work to the most recent studies. Genes. 2017;8(1):36.CrossRef
29.
go back to reference Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11–28.CrossRef Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11–28.CrossRef
30.
go back to reference Romond PC, Rustici M, Gonze D, et al. Alternating oscillations and chaos in a model of two coupled biochemical oscillators driving successive phases of the cell cycle. Ann N Y Acad Sci. 1999;879(1):180–93.CrossRef Romond PC, Rustici M, Gonze D, et al. Alternating oscillations and chaos in a model of two coupled biochemical oscillators driving successive phases of the cell cycle. Ann N Y Acad Sci. 1999;879(1):180–93.CrossRef
31.
go back to reference Sigston EAW, Williams BRG. An emergence framework of carcinogenesis. Front Oncol. 2017;7:198.CrossRef Sigston EAW, Williams BRG. An emergence framework of carcinogenesis. Front Oncol. 2017;7:198.CrossRef
32.
go back to reference Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, Amor DJ, Huq A, Petelin L, Nelson M, James PA, Winship I, McNeil JJ, Lacaze P.Correction: Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genet Med. 2019;21(9):2162–3. https://doi.org/10.1038/s41436-019-0515-0. Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, Amor DJ, Huq A, Petelin L, Nelson M, James PA, Winship I, McNeil JJ, Lacaze P.Correction: Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genet Med. 2019;21(9):2162–3. https://​doi.​org/​10.​1038/​s41436-019-0515-0.
Metadata
Title
Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees
Authors
Huan Lin
Gong Zhang
Xu-chao Zhang
Xin-lei Lian
Wen-zhao Zhong
Jian Su
Shi-liang Chen
Yi-long Wu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07528-3

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine